Shattuck Labs, Inc.: Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Shattuck Labs (NASDAQ: STTK) reported Q2 2026 results and clinical updates for SL-325 and SL-846. SL-325 Phase 1 showed a favorable safety profile, 3.7% antidrug antibodies, and durable TL1A/DR3 blockade; RECEPTIVE-CD1 Phase 2b in Crohn’s is expected to start Q3 2026. Cash and investments were $208.3M, funding operations into 2029.
How this was made
The 30-second read
Why it matters
The release combines (1) Phase 1 SL-325 safety and immunogenicity metrics, (2) a planned Phase 2b initiation in Q3 2026 with defined design and endpoints, and (3) balance-sheet strengthening plus an explicit funding runway into 2029. Together, these can shift near-term valuation expectations for development-stage probability while keeping the major efficacy risk deferred to 2028.
Market read
Traders can reassess STTK’s near-term catalyst path (Phase 2b start timing) and balance-sheet risk (runway into 2029) based on newly disclosed Phase 1 SL-325 metrics and Q2 financials.
What to watch
The article does not provide quantitative Phase 1 efficacy signals, and the cash runway into 2029 may reduce urgency for near-term financing, potentially dampening short-term catalyst intensity despite the capital raise.
Background
Shattuck Labs is a clinical-stage biotech developing DR3-blocking monoclonal and bispecific antibodies for inflammatory and immune-mediated diseases, led by SL-325 (DR3 blocking) and SL-846 (DR3 x IL-23R bispecific).
Ticker impact
Shattuck reported Phase 1 SL-325 results showing durable DR3 blockade, low antidrug antibody rate (3.7%), and expects RECEPTIVE-CD1 Phase 2b to start Q3 2026.
Near-term upside bias versus peers on improved probability of success, with volatility around biotech trial-risk headlines.
The article discloses specific Phase 1 immunogenicity and pharmacodynamic durability metrics and provides a concrete Phase 2b initiation window, which can re-rate development-stage probability. However, no Phase 2 efficacy results are yet provided, limiting conviction on magnitude.
Market effects
Reinforces investor appetite for DR3/TL1A axis immunology programs and may increase relative interest in similar inflammatory disease antibody platforms.
Limited, primarily affects US biotech sentiment and small-cap growth risk appetite.
Moderate, as Crohn’s immunology trial timelines can influence global biotech comps, but no cross-border regulatory or partnership news is disclosed.
Counterpoint
Favorable Phase 1 pharmacodynamics and safety do not guarantee Phase 2 endoscopic response; the key efficacy readout is still expected in 1H 2028.
Key entities
- companyShattuck Labs, Inc.
NASDAQ-listed clinical-stage biotech reporting Q2 2026 results and SL-325/SL-846 program updates.
- product_candidateSL-325
Lead DR3 blocking antibody; Phase 1 showed low antidrug antibodies (3.7%) and durable TL1A binding blockade; RECEPTIVE-CD1 Phase 2b expected to start Q3 2026.
- clinical_trialRECEPTIVE-CD1
Phase 2b Crohn’s disease trial design: randomized, double-blind, placebo-controlled; primary endpoint endoscopic response at 12 weeks; data expected 1H 2028.
- product_candidateSL-846
DR3 x IL-23R bispecific with IND-enabling GLP toxicology ongoing; initial Phase 1 data expected in 2027.
